J
Joseph A. Jakubowski
Researcher at Eli Lilly and Company
Publications - 10
Citations - 802
Joseph A. Jakubowski is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Prasugrel & Clopidogrel. The author has an hindex of 7, co-authored 10 publications receiving 763 citations.
Papers
More filters
Journal ArticleDOI
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin,Christoph Varenhorst,Stefan James,David Erlinge,Oscar Ö. Braun,Joseph A. Jakubowski,Atsuhiro Sugidachi,Kenneth J. Winters,Agneta Siegbahn +8 more
TL;DR: In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite.
Journal ArticleDOI
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
David Erlinge,Christoph Varenhorst,Oscar Ö. Braun,Stefan James,Kenneth J. Winters,Joseph A. Jakubowski,John T. Brandt,Atsuhiro Sugidachi,Agneta Siegbahn,Lars Wallentin +9 more
TL;DR: The mechanism of incomplete platelet inhibition in clopidogrel poor-responder groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y(12) receptor function.
Journal ArticleDOI
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
David Erlinge,Jurriën M. ten Berg,David P. Foley,Dominick J. Angiolillo,Henrik Wagner,Patricia B. Brown,Chunmei Zhou,Junxiang Luo,Joseph A. Jakubowski,Brian A. Moser,David S. Small,Thomas O. Bergmeijer,Stefan James,Kenneth J. Winters +13 more
TL;DR: In aspirin-treated patients with CAD, prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar extent as pr asugrel 10 mg in HBW patients and resulted in greater platelet inhibition, lower HPR, and similar bleeding rates compared with clopidogrel.
Journal ArticleDOI
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients
Henrik Wagner,Dominick J. Angiolillo,Jurriën M. ten Berg,Thomas O. Bergmeijer,Joseph A. Jakubowski,David S. Small,Brian A. Moser,Chunmei Zhou,Patricia B. Brown,Stefan James,Kenneth J. Winters,David Erlinge +11 more
TL;DR: HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel.
Journal ArticleDOI
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel : A retrospective analysis of the FEATHER study
Joseph A. Jakubowski,Dominick J. Angiolillo,Chunmei Zhou,David S. Small,Brian A. Moser,Jurriën M. ten Berg,Patricia B. Brown,Stefan James,Kenneth J. Winters,David Erlinge +9 more
TL;DR: Using a comprehensive selection of body size indices, AM exposures, platelet function tests, and thienopyridine doses, a consistent inverse relationship between body size and response to clopidogrel and prasugrel is demonstrated.